The Cancer Drug England Couldn't Afford Just Got a Second Chance

What Changed

Two things unlocked the deal. First, AstraZeneca and Daiichi Sankyo agreed to a confidential commercial arrangement with NHS England. The exact discount isn't public (it never is in these deals), but it was enough to move the needle.

Second, NICE itself changed. The agency updated its evaluation methods under the UK-US Pharmaceutical Pricing Agreement, which shifted the cost-effectiveness thresholds it uses. In other words, the goalposts moved and the drug got cheaper. Both sides gave ground.

The result: NICE published final draft guidance recommending Enhertu for adults with HER2-low metastatic or unresectable breast cancer who have already had chemotherapy in the metastatic setting, or whose cancer returned during or within six months of adjuvant chemotherapy. Access began immediately.

Why Enhertu Matters Beyond England

This isn't just a UK story. Enhertu is the top-selling ADC on the planet, and its trajectory looks more like a rocket than a plateau.

In fiscal year 2025, Daiichi Sankyo reported global product sales of about ¥698.4 billion for the drug, a jump of 26.3% over the prior year. AstraZeneca's share came in at $2.775 billion, up 40%. When you combine both partners' numbers, global alliance sales approached $5 billion.

The growth isn't slowing down either. Daiichi Sankyo's forecast for fiscal 2026 is ¥861.3 billion in global product sales, implying another 23% increase. The U.S. remains the biggest market, but Europe contributed ¥174.8 billion in FY2025 sales, a figure that should climb now that England's NHS is on board.

The Bigger European Picture

England's green light fits into a broader pattern of European expansion. In 2025, Enhertu won EU approval for HR-positive, HER2-low/HER2-ultralow metastatic breast cancer after endocrine therapy. In 2026, it picked up two more EU approvals: one for HER2-positive solid tumors (a tumor-agnostic indication, meaning it works regardless of where the cancer started) and another for first-line HER2-positive metastatic breast cancer in combination with pertuzumab.

That last one is significant. Industry coverage described it as ending a "10-year EU gap in frontline breast cancer" treatment. AstraZeneca disclosed milestone payments of $25 million and $100 million tied to those EU approvals, a signal of how much commercial weight these decisions carry.

But regulatory approval in the EU doesn't mean automatic reimbursement. Each country negotiates its own pricing deal with the drugmakers. England's experience is a case study in how long that process can take, and how messy it can get when a health system's budget collides with a blockbuster drug's price tag.

What This Means for Patients

For the roughly 1,000 patients per year who are eligible in England, the practical impact is straightforward. Before September 17, their oncologist couldn't prescribe Enhertu through the NHS for HER2-low advanced breast cancer. Now they can.

Trial data from 2022 showed the drug extended survival by about six months compared with standard chemotherapy. It also delayed disease progression, giving patients more time before their cancer worsened. Those numbers may sound modest in the abstract, but for someone living with metastatic breast cancer, six months is not a rounding error.

The Takeaway

Enhertu's England saga is a microcosm of a tension that defines modern healthcare. Breakthrough drugs are getting better, and they're getting more expensive. Single-payer systems like the NHS have to decide what they can afford, and drugmakers have to decide how much margin they're willing to sacrifice for access.

This time, both sides blinked. The drug is in; the price is secret; and about a thousand patients a year just got an option they didn't have last week. For AstraZeneca and Daiichi Sankyo, it's another piece of a $5 billion puzzle clicking into place. For the NHS, it's the cost of staying current in the age of precision oncology.

And for the women who've been watching Scotland's patients get this drug since 2023? It's about time.

ALS Just Broke Another Heart. This Time It Was Novartis.

Novartis killed its ALS drug lifonebart after a Phase 2 trial missed every endpoint, adding to a decades-long streak of industry failures against one of neuroscience's most stubborn diseases. But the company's next move tells a different story.